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Abstract
Aims Cardiac cachexia is a wasting syndrome characterized by chronic inflammation and high mortality. Fibroblast growth
factor 21 (FGF-21) and monocyte chemoattractant protein 1 (MCP-1) are associated with cardiovascular disease and systemic
inflammation. We investigated FGF-21 and MCP-1 in relations to cardiac function, inflammation, and wasting in patients with
heart failure with reduced ejection fraction (HFrEF) and cardiac cachexia.
Methods and results Plasma FGF-21 and MCP-1 were measured in a cross-sectional study among the three study groups: 19
patients with HFrEF with cardiac cachexia, 19 patients with HFrEF without cachexia, and 19 patients with ischaemic heart
disease and preserved ejection fraction. Patients with HFrEF and cardiac cachexia displayed higher FGF-21 levels median
(inter quantile range) 381 (232–577) pg/mL than patients with HFrEF without cachexia 224 (179–309) pg/mL and ischaemic
heart disease patients 221 (156–308) pg/mL (P = 0.0496). No difference in MCP-1 levels were found among the
groups (P = 0.345). In a multivariable regression analysis, FGF-21 (logarithm 2) was independently associated with interleukin
6 (logarithm 2) (P = 0.015) and lower muscle mass (P = 0.043), while no relation with N-terminal pro-hormone brain natriuretic
peptide was observed.
Conclusions Fibroblast growth factor 21 (FGF-21) levels were elevated in patients with HFrEF and cardiac cachexia, which
could be mediated by increased inflammation and muscle wasting rather than impaired cardiac function.
Keywords Fibroblast growth factor 21; FGF-21; Monocyte chemoattractant protein 1; Cardiac cachexia; Muscle wasting; Heart failure
with reduced ejection fraction
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Introduction
Cardiac cachexia is a wasting syndrome characterized by un-
intentional weight loss and a poor prognosis1. The wasting
syndrome is prevalent in 15–20% of patients with heart fail-
ure (HF) with reduced ejection fraction (HFrEF).2,3 Patients
with cardiac cachexia present with symptoms such as an-
orexia, loss of muscle mass, and reduced functional capacity.4
The pathophysiology of cardiac cachexia has been described
as a state of catabolic dysfunction characterized by insulin
resistance and chronic inflammation, possibly mediated by in-
creased neurohormonal activation.5–7 The mechanisms, how-
ever, in the development of cardiac cachexia are still not well
understood. Biomarkers that could generate more knowledge
of the pathophysiological mechanisms behind the progres-
sion of stable HFrEF into cardiac cachexia would thus be of
great clinical importance. Fibroblast growth factor 21
(FGF-21) is a novel regulator in glucose and lipid metabolism8
and notably has demonstrated cardio protective effects in
experimental studies by reducing cardiac inflammation in
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response to cardiac stress.9 In humans, increased circulating
FGF-21 levels have been reported in several conditions re-
lated to cardiac cachexia, such as HF, systemic inflammation,
insulin resistance, and myopathy, and high FGF-21 is associ-
ated with impaired outcome.10–13 Therefore, investigating
the relationship between FGF-21, inflammation, and muscle
wasting in HFrEF with cardiac cachexia is of great clinical
importance.
Monocyte chemoattractant protein 1 (MCP-1) is one of the
key chemokines regulating migration and infiltration of in-
flammatory cells essential for the cardiac remodelling and
progressive impairment in HFrEF.14,15 The impact of MCP-1
in patients with HFrEF is controversial as both elevated and
low circulating levels have been reported.16–18 Furthermore,
the effect of cardiac cachexia on MCP-1 levels has yet to be
evaluated.
The aim of this study was to investigate plasma levels of
circulating FGF-21 and MCP-1 in patients with HFrEF with
and without cardiac cachexia, as compared with patients with
ischaemic heart disease (IHD), and further to assess the rela-
tionship between these biomarkers and inflammation, mus-
cle wasting, and cardiac function.
Methods
Study population
A total of 238 non-diabetic patients with HFrEF were
screened for cardiac cachexia at the HF outpatient clinic at
Copenhagen University Hospital, Herlev and Gentofte,
Denmark, from October 2008 to January 2011. We identified
29 patients with cardiac cachexia, four were excluded due to
severe co-morbidity (chronic obstructive pulmonary disease
and cancer), and six declined to participate. Thus, 19 patients
with HFrEF and cardiac cachexia were included in the study
(the screening methods have previously been described in
details2). Two control groups of equal size (n = 19) were re-
cruited from the approximately 500 patients attending the
HF outpatient clinic and the outpatient cardiology clinic at Co-
penhagen University Hospital, Herlev and Gentofte, Den-
mark: one control group with HFrEF without cachexia and a
second control group (IHD) with prior myocardial infarction,
preserved left ventricle ejection fraction (LVEF >45%) and
without symptoms of HF. Each included patient with cardiac
cachexia was individually matched by sex, age, and kidney
function with the two controls. Patients with IHD were cho-
sen as controls, because IHD was expected to be a significant
co-morbidity among patients with HFrEF; and IHD was seen
as the most similar patient group according to underlying pri-
mary and metabolic disorders. To meet the inclusion criteria,
patients with HFrEF should be clinically stable, with no recent
hospital admission and on maximum tolerated dose of
evidence-based HF medicine within the last 6 months. Car-
diac cachexia was defined as unintentional non-oedematous
weight loss above 5% within the last 6 months.19,20 HFrEF
was assessed at enrolment by echocardiography; all scans
were performed by the same investigator. HFrEF was defined
as LVEF <45% in combination with symptoms according to
the New York Heart Association (NYHA) classification.
Ethics
The study was approved by the Capital Regional Committee
on Health Research Ethics in Denmark. The investigations
were conducted with respect to the principles outlined in
the Declaration of Helsinki. Oral and written informed con-
sent were obtained from all participants prior to study
inclusion.
Laboratory assessments
Venous blood samples were drawn in the morning after a
minimum of 8 h of overnight fast and stored in aliquots at
80°C until analysis. First void morning urine samples were
collected. EDTA-plasma levels of FGF-21, MCP-1, interleukin
6 (IL-6), and mid-regional pro-atrial natriuretic peptide (MR-
proANP) were measured by enzyme-linked immunosorbent
assay [Quantikine, R&D Systems, Abingdon, UK, FGF-21:
intra-assay and inter-assay coefficient of variation (CV):
<3.9%, 5.2–10.9%; MCP-1: CV < 7.8%, 4.6–6.7%; IL-6: CV <
7%; MR-proANP: BRAHMS, Hennigsdorf, Germany, CV <
6.5%, 5–20%].21,22 N-terminal pro-hormone brain natriuretic
peptide (NT-proBNP), high sensitive C-reactive protein, lipids,
plasma glucose, creatinine, and urine-albumin and urine-
creatinine as albumin/creatinine ratio were determined by
routine in-house analyses at the Department of Biochemistry,
Copenhagen University Hospital, Herlev and Gentofte,
Denmark. Insulin resistance was estimated by fasting plasma
glucose and insulin according to the Homeostasis Model As-
sessment Index .23 Estimated glomerular filtration rate (eGFR)
was calculated as measurement of kidney function using the
Modification of Diet in Renal Disease formula.24
Body composition measurements
Total fat mass, android, and gynoid fat mass and fat-free
mass were determined by dual-energy X-ray absorptiometry
(Lunar Prodigy DXA scanner, software version 10.51, GE Med-
ical Systems, Wisconsin, USA). The method is a previously val-
idated method to determine body composition with high
accuracy and reproducibility.25
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Statistical analyses
Continuous variables are presented as mean ± standard devi-
ation (SD) if assumptions of normal distribution were ade-
quately fulfilled by evaluating linearity of residuals in
quantile plots. Group comparisons were tested by ANOVA.
Non-parametric variables and variables not fulfilling homoge-
neity of variance between the groups (P < 0.05 in Levene’s
test) are presented as median (inter quantile range) with
group comparisons by χ2/Kruskal–Wallis test. Post hoc com-
parisons among the three groups were tested with Bonferroni
correction. Continuous variables with skewed distributions
[FGF-21, MCP-1, NT-proBNP, MR-proANP, IL-6, high sensitive
C-reactive protein, homeostatic model assessment of insulin
resistance (HOMA-IR), and albumin/creatinine ratio] were log-
arithmically transformed using logarithm 2 (log2) before en-
tered in the linear regression analyses. Univariate linear
regression analyses were performed to assess associations be-
tween FGF-21 and MCP-1, respectively, and markers of in-
flammation, wasting, cardiac function, lipid and glucose
metabolism, and kidney function. Correction for multiple test-
ing was performed by Benjamini–Hochberg’s false discovery
rate.26 Two multivariable linear regression analyses were cre-
ated to evaluate parameters predictive of FGF-21 and MCP-1
levels and preformed with stepwise backward elimination.
Adjusting for age and sex as well, parameters were included
in the models if P< 0.10 in univariate regression analyses. Ac-
cordingly, in a model of predictors of FGF-21 levels, the follow-
ing parameters were included: age, sex, IL-6, NT-proBNP, total
fat-free mass, total cholesterol, and haemoglobin A1c
(HbA1c). In the model of MCP-1, the following variables were
included: age, sex, eGFR, HbA1c, total cholesterol, total fat
mass, and IHD. Patient Number 35 had a plasma FGF-21 con-
centration of 8069 pg/mL, which exceeded the assay detec-
tion limit of 2000 pg/mL, why several dilutions were
performed. This value varies greatly from the rest of the study
participants with 1550 pg/mL as the second highest value
measured and a 95% percentile of 1280 pg/mL. The outlier
status was then tested: Cook’s distance was 0.288 in a univar-
iate regression analysis between FGF-21 (log2) and IL-6 (log2),
which exceeds the recommended value of 4n ¼ 457 ¼ 0:07 for
identifying outliers.27 The measured concentration can thus
be considered as an extreme outlier and has therefore been
excluded from the FGF-21 regression analyses. P-values
<0.05 were considered statistically significant. Statistical
analyses were performed using SPSS version 22 and RStudio
version 1.0.136.
Results
The main characteristics of the study participants are pre-
sented in Table 1. Mean (±SD) age across groups was
78.0 (±7.1) years with a male/female ratio of 15/4 in all
groups. Patients with HFrEF and cardiac cachexia had lower
LVEF (P < 0.001) than the two other groups and elevated
biomarkers of inflammation and natriuretic peptides, mea-
sured as IL-6 (P = 0.042), NT-proBNP (P < 0.001), and
MR-proANP (P < 0.001) (Table 1). No difference in diastolic
dysfunction, as assessed by E/e’ ratio, was observed be-
tween the groups. As expected, body mass index (BMI)
(P < 0.001) and total fat mass (P = 0.005) were markedly
lower in the group with HFrEF and cardiac cachexia as com-
pared with the two other groups. Lower fat-free mass was
observed among patients with HFrEF and cardiac cachexia
(45.4 vs. 49.1 kg in patients with HFrEF without cachexia)
although the difference was not statistically significant
(P = 0.053 for index). No difference in parameters of
glucose metabolism, as assessed by HbA1c or HOMA-IR,
was found among the groups (Table 1). Regarding the
diagnostic criteria of cardiac cachexia, the group with
cardiac cachexia had a mean (±SD) unintentional weight
loss of 9.4 (±0.7) % equal to 6.7 (±0.6) kg within 6 months
prior to enrolment.
Fibroblast growth factor 21 and clinical
characteristics of cardiac cachexia
Plasma FGF-21 levels were elevated in patients with HFrEF
and cardiac cachexia median (inter quantile range) 381
(232–577) pg/mL, as compared with patients with HFrEF
without cachexia 224 (179–309) pg/mL and IHD patients
221 (156–308) pg/mL (P = 0.0496) (Table 1 and Figure
1A). FGF-21 (log2) was associated with increased IL-6
(log2) (B = 0.454, P = 0.001) and with reduced fat-free
mass (B = –0.047, P = 0.006) (Figure 2 and Supporting
Information, Table S1). There were no relations between
FGF-21 and cardiac function measured by LVEF (P = 0.165),
E/e’ ratio (P = 0.402), NYHA class (P = 0.274), or NT-proBNP
(log2) (P = 0.087) across groups (Supporting Information,
Table S1). Notably, the high levels of FGF-21 showed no
association with impaired kidney function, as assessed by
eGFR. With regard to lipid and glucose metabolism,
FGF-21 was univariate associated with total cholesterol
(P = 0.017), whereas no associations with glucose
metabolism, as assessed by HbA1c or HOMA-IR, were found
(HbA1c: P = 0.088, HOMA-IR: P = 0.906) (Supporting
Information, Table S1). After correction for multiple testing
of the univariate regression analyses, only IL-6 remained
significantly univariate associated with FGF-21 (Supporting
Information, Table S1). The predictors of increased FGF-21
levels were further evaluated in a multivariable linear
regression model. In this model, higher IL-6 (P = 0.015)
and total cholesterol (P = 0.010), and lower fat-free mass
(P = 0.043) and HbA1c (P = 0.041) were independently
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associated with FGF-21. No predictive value of NT-proBNP
was found (P = 0.993) (Table 2).
Monocyte chemoattractant protein 1 levels and
clinical characteristics of cardiac cachexia
No difference in plasma MCP-1 levels was found among the
groups (P = 0.345) (Table 1 and Figure 1B). Impaired
kidney function, as assessed by eGFR (P = 0.014), HbA1c
(P = 0.016), and lower total fat mass (P = 0.023), was
univariate associated with MCP-1 (log2) (Supporting Infor-
mation, Table S1). MCP-1 showed no relations to cardiac
function, inflammation, or muscle wasting (Supporting In-
formation, Table S1), although a trend towards an inverse
association with IHD was observed (P = 0.057). After
correction for multiple testing of the univariate regression
analyses, no variables remained significantly univariate
associated with MCP-1 (Supporting Information, Table S1).
In a multivariable linear regression analysis adjusted
for sex and age, MCP-1 (log2) was independently associ-
ated with total cholesterol (P = 0.008) and inversely
Table 1 Characteristics of participants
HFrEF with cachexia (n = 19) HFrEF with cachexia (n = 19) IHD (n = 19) P-value
Demographics
Sex, F/M 4/15 4/15 4/15 1.000d
Agea, years 77.3 (6.7) 78.9 (9.0) 78.8 (7.2) 0.760c
Smoking, n (%) 13 (68) 15 (79) 14 (74) 0.480d
Metabolism
Total cholesterola, mmol/L 4.2 (0.7) 4.6 (0.9) 4.0 (0.9) 0.059c
LDL cholesterola, mmol/L 2.2 (0.7) 2.5 (0.8) 2.2 (0.7) 0.322c
HOMA-IRb 1.25 (0.74–2.07) 1.15 (0.95–2.39) 1.74 (0.97–2.44) 0.480d
HbA1ca, mmol/L 5.7 (0.5) 6.0 (0.3) 5.8 (0.3) 0.135c
eGFRa, mL/min/1.73 m2 64 (20) 64 (22) 68 (16) 0.742c#
U-Albumin/creatinineb, mg/mmol 1.1 (0.6–2.3) 1.0 (0.5–2.2) 0.5 (0.2–1.7) 0.086d
Cardiac measures
HFrEF durationb, months 12 (11–18) 24 (15–36) — 0.033d
NYHA class I/II, n (%) 17 (89) 18 (95) — 0.310d
Ischaemic heart disease, n (%) 14 (74)* 17 (89) 19 (100) 0.045d
Atrial fibrillation, n (%) 7 (37)* 5 (26) 0 0.016d
Systolic blood pressurea, mmHg 126 (14)* 138 (16) 146 (16) 0.001c
Pulsea, bpm 70 (14) 67 (14) 62 (8) 0.127c
LVEFa, % 32 (8) 38 (8) 60 (9)** <0.001c
E/e’ ratioa 7.22 (2.72) 10.86 (10.26) 9.24 (3.41) 0.227c
Body composition
BMIa, kg/m2 22.3 (2.7)** 26.1 (3.7) 26.3 (2.7) <0.001c
Total fat massa, kg 15.7 (6.8)** 22.5 (9.0) 23.9 (7.6) 0.005c
Android fat massa, kg 4.9 (3.3)** 9.3 (5.7) 10.2 (4.9) 0.002c
Gynoid fat massa, kg 5.4 (3.8) 8.2 (5.2) 8.7 (4.8) 0.070c
Total fat-free massa, kg 45.4 (5.9) 49.1 (7.3) 49.4 (8.3) 0.179c
Biomarkers
NT-proBNPb, ng/L 2310 (1430–3860)** 1090 (508–2110) 423 (140–1100) <0.001d
MR-proANPb, pmol/L 364 (316–500)** 310 (152–394) 186 (126–308) <0.001d
hsCRPb, mg/L 1.9 (0.8–3.9) 1.6 (0.7–4.4) 0.9 (0.7–2.0) 0.296d
IL-6b, pg/mL 5.3 (2.8–6.8)* 2.8 (2.0–6.9) 2.6 (1.7–3.6) 0.042d
FGF-21b, pg/mL 381 (232–577) 224 (179–309) 221 (156–308) 0.0496d
MCP-1b, pg/mL 252 (205–310) 229 (178–291) 213 (196–251) 0.345d
Medication
Loop diuretics, n (%) 18 (95) 11 (58) 2 (11) 0.001d
ACE-I/ARB, n (%) 19 (100) 19 (100) 11 (58) 0.001d
Beta-blockers, n (%) 19 (100) 16 (84) 15 (79) 0.125d
Statins, n (%) 16 (84) 17 (89) 19 (100) 0.220d
BMI, body mass index; eGFR, estimated glomerular filtration rate; E/e’ ratio, early diastolic transmitral flow velocity/early diastolic mitral
annular velocity; FGF-21, fibroblast growth factor 21; HFrEF, heart failure with reduced ejection fraction; HOMA-IR, homeostatic model
assessment of insulin resistance; HbA1c, haemoglobin A1c; hsCRP, high sensitive C-reactive protein; IHD, ischaemic heart disease; IL-6, in-
terleukin 6; LDL, low-density lipoprotein; LVEF, left ventricle ejection fraction; MR-proANP, mid-regional pro-atrial natriuretic peptide;
MCP-1, monocyte chemoattractant protein 1; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-brain natriuretic peptide.
aMean (SD).
bMedian (inter quantile range).
cOne-way ANOVA
dχ2/Kruskal–Wallis test.
#P = 0.645 when calculated by the CKD-EPI equation.
*Different from the IHDgroup in pairwise comparisons (P<0.05).
**Different from the two other groups in pairwise comparisons (P<0.05).
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associated with total fat mass (P = 0.002) and eGFR (P =
0.011) (Table 2).
Discussion
The main findings of the present study are that plasma FGF-
21 levels are elevated in patients with HFrEF and cardiac ca-
chexia, as compared with patients with HFrEF without cardiac
cachexia and patients with IHD. Higher FGF-21 levels were in-
dependently associated with increased inflammation and
with muscle wasting, as assessed by IL-6 and fat-free mass.
Furthermore, an independent association with total choles-
terol and lower HbA1c levels was found. No relationships be-
tween MCP-1 and cardiac function or the presence of cardiac
cachexia were observed.
We found no association between FGF-21 and impaired
cardiac function, as assessed by NYHA class, LVEF, E/e’ ratio,
or NT-proBNP. Only a limited number of studies describe the
clinical significance of FGF-21 in HF. Planavila et al.28 found in-
creased myocardial expression of FGF-21 in failing human
hearts, and an association of circulating FGF-21 levels and left
ventricular systolic dysfunction has been reported.10
Furthermore, circulating FGF-21 levels have been linked with
diastolic dysfunction in patients with HF with preserved ejec-
tion fraction .29 Although observing comparable FGF-21 levels
in the present study, our data did not support an association
between FGF-21 and systolic or diastolic dysfunction in pa-
tients with HFrEF, as assessed by LVEF and E/e’ ratio. This dis-
crepancy could be a power issue, as our sample size was
smaller than the previous HF studies conducted, or be due
to the difference in study population, as we only enrolled pa-
tients with HFrEF.
We are, to the best of our knowledge, the first to report
elevated FGF-21 levels in patients with cardiac cachexia and
to suggest a possible mechanism of increased inflammation,
as we found an independent association with the well-
established inflammatory biomarker IL-6. The present clinical
findings are supported by experimental studies, where in-
creased FGF-21 expression has been reported in response
to inflammation.30 Further, increased FGF-21 levels are pres-
ent in sepsis with subsequent decreasing FGF-21 levels with
clinical remission.12 Thus, the present study suggests that
the elevated FGF-21 levels in HFrEF and cardiac cachexia are
mediated by the increased inflammation rather than im-
paired cardiac function.
Figure 1 Plasma levels of FGF-21 (A) and MCP-1 (B) according to groups. (A) FGF-21 levels were higher in patients with HFrEF and cardiac cachexia, as
compared with patients with HFrEF without cachexia and patients with IHD (P = 0.0496). (B) No difference in MCP-1 levels was found between the
groups (P = 0.345). Range bars representing minimum and maximum value (outliers excluded). FGF-21, fibroblast growth factor 21; IHD, ischaemic
heart disease; MCP-1, monocyte chemoattractant protein 1.
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We found an independent association between elevated
FGF-21 levels and lower fat-free mass, thus indicating a link
with muscle wasting. Our findings are supported by several
studies in patients with mitochondrial disease, including my-
opathy, where circulating FGF-21 is associated with low BMI
and muscle weakness, a significant symptom of muscle
wasting.13,31 In mice, FGF-21 activates the SIRT I/AMPK/
PGC-α signalling pathway favouring the transition of larger
anaerobe myofibers into smaller aerobic myofibers.32
Because hepatic FGF-21 expression is elevated in the fasted
state,33 the authors suggest FGF-21 as a possible explanation
of the muscle atrophy seen in conditions with fasting.32 An-
orexia being a significant symptom of cardiac cachexia,4 de-
creased energy intake could be a possible mechanism
behind the association between FGF-21 and muscle wasting
observed in the present study.
Notably, as FGF-21 showed no association with NT-
proBNP, it may bear clinical implications as a biomarker in
Figure 2 Scatter plots and regression lines with 95% confidence interval bands representing associations between FGF-21 and IL-6 (A) and fat-free
mass (B). FGF-21 (log2) was univariate associated with inflammation biomarker IL-6 (log2) (A) and reduced fat-free mass (B). FGF-21, fibroblast growth
factor 21; IL-6, interleukin 6; log2, logarithm 2.
A
B
M. Refsgaard Holm et al.
DOI: 10.1002/ehf2.12502
988
ESC Heart Failure 2019; 6: 983–991
predicting cardiac cachexia in combination with natriuretic
peptides. Currently, cardiac cachexia is first diagnosable af-
ter significant weight loss and muscle wasting have oc-
curred, making it difficult to revers or slow down the
wasting process with only limited treatment available.34
As cardiac cachexia effects up to 20% of patients with
HFrEF, new diagnostic approaches are urgent.2,3 Several
new biomarkers in cachexia are investigated, including
TGF-ß and IL-8.35 FGF-21 emerges as a promising novel bio-
marker in various diseases with cachexia. Increased FGF-21
levels have recently been reported in geriatric patients with
cachexia, as compared with geriatric patients without ca-
chexia. FGF-21 was correlated with weight loss and an-
orexia, although the impact of sarcopenia was not
assessed.36 Further, increased FGF-21 levels are also re-
ported in patients with renal cancer, as compared with
healthy controls37, and in end-stage kidney disease, where
high FGF-21 is associated with impaired outcome.38 We
found increased FGF-21 levels in patients with cardiac ca-
chexia, as well as associations between FGF-21 and the
central cardiac cachexia disorders, chronic inflammation,
and muscle wasting. Therefore, FGF-21 could have potential
as a diagnostic biomarker in predicting HF patients with
high risk of cardiac cachexia. Larger prospective studies
are warranted to assess the clinical significance of FGF-21
as a diagnostic biomarker in HF and cardiac cachexia.
Previous studies have shown that circulating FGF-21
levels are associated with dyslipidemia and insulin resis-
tance in patients with obesity.39 We, however, found no as-
sociation with insulin resistance or fat mass, although an
association with total cholesterol was observed. Zhang
et al.39 found the association between FGF-21 and insulin
resistance was eliminated when adjusting for BMI. As our
study population mostly consisted of non-obese cardiac pa-
tients, this could explain the lack of relationship between
FGF-21 and insulin resistance. Further, Zhang et al. only
evaluated BMI, and not body composition, why the role
of sarcopenia in the elevated FGF-21 levels reported in in-
sulin resistance cannot be assessed. We did, however, find
an inverse association with HbA1c. FGF-21 stimulates glu-
cose uptake in adipose tissue in a dose dependent man-
ner.40 The elevated FGF-21 levels in HFrEF and cardiac
cachexia may therefore have lowered blood glucose levels
explaining the inverse association between FGF-21 and
HbA1c.
The available literature is inconsistent with regard to the
effect of MCP-1 in CHF, as both increased and decreased car-
diac expression of MCP-1 have been reported in failing hu-
man hearts.17,18 Regarding circulating MCP-1, an association
between MCP-1 levels and NYHA class has been reported in
patients with HFrEF and HF with preserved ejection frac-
tion.16 We could not demonstrate increased MCP-1 levels in
patients with HFrEF with or without cardiac cachexia as com-
pared with IHD and normal LVEF. Therefore, the value of
MCP-1 as a biomarker in HFrEF or cardiac cachexia is
questionable.
The current study has several limitations. The sample
size was relatively small, and the cross-sectional design
limits analysis of causality. We chose to have equal class
sizes, which may have decreased the power of the statisti-
cal methods; furthermore, only patients with signed in-
formed consent were allowed in the study analyses. We
did not collect data on statin doses. Although there was
no difference in the number of patients receiving statins
between the groups, the influence of possible higher statin
doses in the IHD group cannot be assessed. We excluded
HF patients with preserved ejection fraction, why our find-
ings may not apply for these patients. Larger studies are
needed to confirm the association of FGF-21 and cardiac
cachexia.
Table 2 Multivariable linear regression analyses assessing predictors of FGF-21 and MCP-1
FGF-21a, pg/mL MCP-1a, pg/mL
B (95% CI) P-value B (95% CI) P-value
Sex –0.654 (–1.418; 0.110) 0.092 –0.038 (–0.375; 0.298) 0.820
Age, years –0.022 (–0.056; 0.012) 0.199 0.009 (–0.010; 0.028) 0.344
HD — — –0.272 (–0.632; 0.088) 0.135
Metabolism
Total cholesterol, mmol/L 0.379 (0.094; 0.664) 0.010 0.189 (0.052; 0.325) 0.008
HbA1c, mmol/L –0.616 (–1.205; –0.027) 0.041 0.250 (–0.054; 0.554) 0.105
eGFR, mL/min/1.73 m2 — — –0.008 (–0.014; –0.002) 0.011
Body composition
Total fat-free mass, kg –0.045 (–0.088; –0.001) 0.043 — —
Total fat mass, kg — — –0.022 (–0.036; –0.009) 0.002
Biomarkers
IL-6a, pg/mL 0.315 (0.063; 0.567) 0.015 — —
NT-proBNPa, ng/L –0.001 (–0.151; 0.149) 0.993 — —
B (95% CI), unstandardized regression coefficient (95% confidence interval); FGF-21, fibroblast growth factor 21; HbA1c, haemoglobin
A1c; IHD, ischaemic heart disease; IL-6, interleukin 6; MCP-1, monocyte chemoattractant protein 1; NT-proBNP, N-terminal pro-brain na-
triuretic peptide.
aLogarithm 2 transformed.
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Conclusions
In conclusion, elevated FGF-21 levels are present in patients
with HFrEF and cardiac cachexia. We found no association be-
tween MCP-1 and cardiac function or cardiac cachexia. The
present study suggests that the elevated FGF-21 levels in car-
diac cachexia are mediated by increased inflammation and
muscle wasting rather than impaired cardiac function. FGF-
21 could, therefore, bear clinical implications in predicting
muscle wasting in cardiac cachexia.
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